A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
| Autor: | Kasi, Anup, Phadnis, Milind A., Al-Rajabi, Raed Moh'd Taiseer, Baranda, Joaquina Celebre, Li, Haoran, Carroll, Erin, Belcher, Cathey, Bradbury, Shannon, Collins, Zachary, Sun, Weijing |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS719-TPS719, 117p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|